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Persistent SARS-CoV-2 infection: the urgent need for access 
to treatment and trials
The management of patients presenting to health-
care services with SARS-CoV-2 infection has developed 
rapidly over the past year, driven by the findings of 
high-quality randomised trials. These trials have been 
justifiably focused on preventing severe disease in 
patients with very early infection and on the treatment 
of acutely unwell patients. However, although applicable 
to the majority of patients, it has become apparent 
that there are specific patient cohorts not well served 
by these studies, to whom their conclusions might not 
apply, and who as a consequence risk missing out on 
access to potentially beneficial treatments.
Patients with persistent SARS-CoV-2 infection are 
one such cohort. Persistent SARS-CoV-2 infection can 
occur in certain immunocompromised people, such as 
those with primary immunodeficiency or recipients of 
immunosuppressive therapy (eg, B cell-depleting anti-
CD20 treatment or chimeric antigen receptor T-cell 
therapy following bone marrow transplantation). These 
individuals are well known to be at risk of other chronic 
viral infections, including norovirus and rhinovirus.
Although some patients might experience severe 
disease and fatal outcomes, many others might not 
require hospitalisation but are unable to clear their 
coronavirus infection. They experience months of 
cough, fever, breathlessness, and debilitation, often 
with episodes of apparent clinical recovery followed by 
deterioration. Reports have confirmed that viable virus 
can be cultured from such individuals, many months 
after the initial infection, and they commonly do not 
develop an anti-SARS-CoV-2 antibody response. The 
antiviral drug remdesivir can ease symptoms and has 
been associated with viral clearance and sustained 
improvement in some patients, yet in others it 
appears to produce only a transient drop in viral load, 
with recrudescence once treatment stops.1 Antibody 
therapy, whether with convalescent plasma or synthetic 
monoclonal antibody cocktails, holds promise. There 
are convincing reports of complete symptom resolution 
and sustained viral clearance after receipt of these 
therapies in patients who have had many months 
of illness.2 Over 30 such cases have been reported in 
the UK, but the total number of affected individuals 
is not known. Data collated from these cases confirm 
the clinical impression that remdesivir monotherapy 
is associated with frequent relapses or persistent PCR 
positivity, but monoclonal antibody therapy combined 
with remdesivir has been associated with near-universal 
viral clearance and clinical recovery.
There is currently no access to these treatments in the 
UK for patients with persistent infection. There does 
not appear to be support for compassionate use access 
from pharmaceutical companies, and convalescent 
plasma has been withdrawn following demonstration 
that it is ineffective in immunocompetent hospitalised 
patients.3 Synthetic antibody therapy has already been 
authorised for emergency use in the EU and the USA 
for patients with mild or moderate disease, and work 
is in progress to define the criteria for access to these 
therapies in the UK, in light of the preliminary results 
of the casirivimab plus imdevimab (REGN-COV2) 
arm of RECOVERY.4 These results do provide a way 
forward. Although this trial was not designed to 
address treatment strategies in patients with persistent 
infection, it did find a mortality benefit in seronegative 
patients. This finding supports the rationale for benefit 
in patients who are unlikely to generate an antibody 
response, although no randomised controlled trial 
conducted specifically within this patient group has 
been published, and such a trial would be challenging 
given small patient numbers.
It is important that any potential benefit for this 
small but important cohort is not overlooked. Beyond 
treatment of sick individuals trapped in hospital 
or at home in perpetual self-isolation with a risk of 
developing chronic lung disease, there are compelling 
public health arguments for attempting a cure. 
Analysis of viral sequences obtained from such patients 
over time suggests ongoing viral evolution within 
immunosuppressed individuals, potentially facilitating 
the emergence of new strains within the wider 
population.5
It has been suggested that such treatments could 
themselves risk driving the selection of resistance, 
and thus any treatment regimen would require close 
monitoring of viral evolution and early recognition 
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of any unintended consequences.5 We agree that such 
monitoring is mandatory and deliverable for these 
patients regardless of treatment. However, rapid viral 
elimination using a combination of antivirals and 
high-titre antibody-based therapy would prevent any 
further evolution. The small patient number need not 
be an impediment to delivery of well designed trials 
of potential therapies. In the absence of such trials, 
a rigorously overseen national treatment protocol 
incorporating the collection of virological and clinical 
outcome data could be delivered safely. Whatever route 
is chosen to develop and deliver therapies, a strategy to 
reduce morbidity and protect public health is needed 
urgently. 
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